These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 21971937)

  • 21. [Study of the possibilities of using a short-term test system in vitro for detection of potential mutagens (carcinogens)].
    Domshlak MG; Sanotskiĭ IV; Serebrianyĭ AM
    Gig Tr Prof Zabol; 1989; (11):47-9. PubMed ID: 2515120
    [No Abstract]   [Full Text] [Related]  

  • 22. The role of mammalian cell mutation assays in mutagenicity and carcinogenicity testing.
    Arlett CF; Cole J
    Mutagenesis; 1988 Nov; 3(6):455-8. PubMed ID: 3070282
    [No Abstract]   [Full Text] [Related]  

  • 23. An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines.
    Sistare FD; Morton D; Alden C; Christensen J; Keller D; Jonghe SD; Storer RD; Reddy MV; Kraynak A; Trela B; Bienvenu JG; Bjurström S; Bosmans V; Brewster D; Colman K; Dominick M; Evans J; Hailey JR; Kinter L; Liu M; Mahrt C; Marien D; Myer J; Perry R; Potenta D; Roth A; Sherratt P; Singer T; Slim R; Soper K; Fransson-Steen R; Stoltz J; Turner O; Turnquist S; van Heerden M; Woicke J; DeGeorge JJ
    Toxicol Pathol; 2011 Jun; 39(4):716-44. PubMed ID: 21666103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. International regulatory needs for development of an IATA for non-genotoxic carcinogenic chemical substances.
    Jacobs MN; Colacci A; Louekari K; Luijten M; Hakkert BC; Paparella M; Vasseur P
    ALTEX; 2016; 33(4):359-392. PubMed ID: 27120445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An overview of environmental mutagenesis in China.
    Hsueh JL; Yin MQ
    Prog Clin Biol Res; 1990; 340E():285-306. PubMed ID: 2392460
    [No Abstract]   [Full Text] [Related]  

  • 26. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens III. Appropriate follow-up testing in vivo.
    Kirkland D; Speit G
    Mutat Res; 2008 Jul; 654(2):114-32. PubMed ID: 18585956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The results of assays in Drosophila as indicators of exposure to carcinogens.
    Vogel EW; Graf U; Frei HJ; Nivard MM
    IARC Sci Publ; 1999; (146):427-70. PubMed ID: 10353398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficiency of the prediction of carcinogenic activities of chemical substances based on scoring somatic mutations in the soybean Glycine max (L.) Merrill].
    Bittueva MM; Abilev SK; Tarasov VA
    Genetika; 2007 Jan; 43(1):78-87. PubMed ID: 17333942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High dose levels are not necessary in rodent studies to detect human carcinogens.
    Monro A; Davies TS
    Cancer Lett; 1993 Dec; 75(3):183-94. PubMed ID: 8313353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detecting and predicting the activity of rodent carcinogens.
    Parry JM
    Mutagenesis; 1994 Jan; 9(1):3-5. PubMed ID: 7911554
    [No Abstract]   [Full Text] [Related]  

  • 31. An integrative test strategy for cancer hazard identification.
    Luijten M; Olthof ED; Hakkert BC; Rorije E; van der Laan JW; Woutersen RA; van Benthem J
    Crit Rev Toxicol; 2016 Aug; 46(7):615-39. PubMed ID: 27142259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple steps in carcinogenesis, multiple carcinogenic factors, and multiple primary tumors: can we develop an appropriate response for cancer prevention?
    Nagao M; Sugimura T
    Drug Metab Rev; 1998 May; 30(2):405-19. PubMed ID: 9606610
    [No Abstract]   [Full Text] [Related]  

  • 33. Value of rodent carcinogenesis bioassays.
    Ward JM
    Toxicol Appl Pharmacol; 2008 Jan; 226(2):212. PubMed ID: 18029286
    [No Abstract]   [Full Text] [Related]  

  • 34. The Syrian hamster embryo cells transformation assay identifies efficiently nongenotoxic carcinogens, and can contribute to alternative, integrated testing strategies.
    Benigni R; Bossa C; Tcheremenskaia O; Battistelli CL; Giuliani A
    Mutat Res Genet Toxicol Environ Mutagen; 2015 Feb; 779():35-8. PubMed ID: 25813724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perspectives on the elimination of animal assays in the assessment of carcinogenicity.
    Nishikawa A
    Regul Toxicol Pharmacol; 2021 Nov; 126():105031. PubMed ID: 34437954
    [No Abstract]   [Full Text] [Related]  

  • 36. Contemporary trends in in vivo and in vitro testing of chemical carcinogens.
    Slamenová D
    Neoplasma; 2001; 48(6):425-34. PubMed ID: 11949832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The mouse carcinogenicity study is no longer a scientifically justifiable core data requirement for the safety assessment of pesticides.
    Billington R; Lewis RW; Mehta JM; Dewhurst I
    Crit Rev Toxicol; 2010 Jan; 40(1):35-49. PubMed ID: 20144135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alternatives to the carcinogenicity bioassay: in silico methods, and the in vitro and in vivo mutagenicity assays.
    Benigni R; Bossa C; Tcheremenskaia O; Giuliani A
    Expert Opin Drug Metab Toxicol; 2010 Jul; 6(7):809-19. PubMed ID: 20438313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hydroquinone: an evaluation of the human risks from its carcinogenic and mutagenic properties.
    McGregor D
    Crit Rev Toxicol; 2007; 37(10):887-914. PubMed ID: 18027166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of genotoxic and non-genotoxic carcinogens in Xpc(-/-)p53(+/-) mice.
    Melis JP; Speksnijder EN; Kuiper RV; Salvatori DC; Schaap MM; Maas S; Robinson J; Verhoef A; van Benthem J; Luijten M; van Steeg H
    Toxicol Appl Pharmacol; 2013 Jan; 266(2):289-97. PubMed ID: 23153559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.